Under the terms of the consulting agreement, effective as of January 17, 2025, Mr. Kelly will provide advisory services to the company from January 2, 2025, through December 31, 2028.

Tempest Therapeutics' executive team has transitioned to consulting agreements as the company explores strategic alternatives. Chief Executive Stephen Brady, Chief Medical Officer Samuel Whiting ...